vs

Side-by-side financial comparison of CITIZENS FINANCIAL SERVICES INC (CZFS) and Pulmonx Corp (LUNG). Click either name above to swap in a different company.

CITIZENS FINANCIAL SERVICES INC is the larger business by last-quarter revenue ($29.6M vs $20.6M, roughly 1.4× Pulmonx Corp). CITIZENS FINANCIAL SERVICES INC runs the higher net margin — 35.4% vs -66.3%, a 101.7% gap on every dollar of revenue. On growth, CITIZENS FINANCIAL SERVICES INC posted the faster year-over-year revenue change (13.0% vs -8.7%). Over the past eight quarters, CITIZENS FINANCIAL SERVICES INC's revenue compounded faster (6.9% CAGR vs -0.5%).

Citizens Financial Group, Inc. is an American bank holding company, headquartered in Providence, Rhode Island. The company owns the bank Citizens Bank, N.A., which operates in the U.S. states of Connecticut, Delaware, Florida, Maryland, Massachusetts, Michigan, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, Rhode Island, Vermont, and Virginia, as well as Washington, DC.

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

CZFS vs LUNG — Head-to-Head

Bigger by revenue
CZFS
CZFS
1.4× larger
CZFS
$29.6M
$20.6M
LUNG
Growing faster (revenue YoY)
CZFS
CZFS
+21.6% gap
CZFS
13.0%
-8.7%
LUNG
Higher net margin
CZFS
CZFS
101.7% more per $
CZFS
35.4%
-66.3%
LUNG
Faster 2-yr revenue CAGR
CZFS
CZFS
Annualised
CZFS
6.9%
-0.5%
LUNG

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CZFS
CZFS
LUNG
LUNG
Revenue
$29.6M
$20.6M
Net Profit
$10.5M
$-13.7M
Gross Margin
77.9%
Operating Margin
44.2%
-40.9%
Net Margin
35.4%
-66.3%
Revenue YoY
13.0%
-8.7%
Net Profit YoY
31.3%
5.5%
EPS (diluted)
$2.17
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CZFS
CZFS
LUNG
LUNG
Q1 26
$20.6M
Q4 25
$29.6M
$22.6M
Q3 25
$29.0M
$21.5M
Q2 25
$27.3M
$23.9M
Q1 25
$26.4M
$22.5M
Q4 24
$26.2M
$23.8M
Q3 24
$25.1M
$20.4M
Q2 24
$24.6M
$20.8M
Net Profit
CZFS
CZFS
LUNG
LUNG
Q1 26
$-13.7M
Q4 25
$10.5M
$-10.4M
Q3 25
$10.0M
$-14.0M
Q2 25
$8.5M
$-15.2M
Q1 25
$7.6M
$-14.4M
Q4 24
$8.0M
$-13.2M
Q3 24
$7.5M
$-14.1M
Q2 24
$5.3M
$-15.3M
Gross Margin
CZFS
CZFS
LUNG
LUNG
Q1 26
77.9%
Q4 25
77.6%
Q3 25
74.7%
Q2 25
72.1%
Q1 25
72.5%
Q4 24
74.0%
Q3 24
73.7%
Q2 24
73.7%
Operating Margin
CZFS
CZFS
LUNG
LUNG
Q1 26
-40.9%
Q4 25
44.2%
-43.8%
Q3 25
42.6%
-66.9%
Q2 25
38.1%
-62.0%
Q1 25
35.5%
-64.6%
Q4 24
37.2%
-56.5%
Q3 24
36.9%
-69.3%
Q2 24
25.9%
-75.2%
Net Margin
CZFS
CZFS
LUNG
LUNG
Q1 26
-66.3%
Q4 25
35.4%
-46.1%
Q3 25
34.5%
-64.9%
Q2 25
31.0%
-63.6%
Q1 25
28.8%
-64.1%
Q4 24
30.5%
-55.4%
Q3 24
30.0%
-69.4%
Q2 24
21.4%
-73.7%
EPS (diluted)
CZFS
CZFS
LUNG
LUNG
Q1 26
$-0.33
Q4 25
$2.17
$-0.25
Q3 25
$2.09
$-0.34
Q2 25
$1.76
$-0.38
Q1 25
$1.60
$-0.36
Q4 24
$1.64
$-0.33
Q3 24
$1.57
$-0.36
Q2 24
$1.10
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CZFS
CZFS
LUNG
LUNG
Cash + ST InvestmentsLiquidity on hand
$34.3M
$61.6M
Total DebtLower is stronger
$37.3M
Stockholders' EquityBook value
$338.1M
$45.8M
Total Assets
$3.1B
$120.0M
Debt / EquityLower = less leverage
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CZFS
CZFS
LUNG
LUNG
Q1 26
$61.6M
Q4 25
$34.3M
$69.8M
Q3 25
$31.1M
$76.5M
Q2 25
$49.5M
$75.5M
Q1 25
$36.8M
$74.6M
Q4 24
$42.2M
$70.9M
Q3 24
$36.8M
$63.3M
Q2 24
$38.4M
$63.5M
Total Debt
CZFS
CZFS
LUNG
LUNG
Q1 26
$37.3M
Q4 25
$37.1M
Q3 25
$37.1M
Q2 25
$37.1M
Q1 25
$37.2M
Q4 24
$37.2M
Q3 24
$37.2M
Q2 24
$37.2M
Stockholders' Equity
CZFS
CZFS
LUNG
LUNG
Q1 26
$45.8M
Q4 25
$338.1M
$54.1M
Q3 25
$327.7M
$60.0M
Q2 25
$313.7M
$69.1M
Q1 25
$308.3M
$77.7M
Q4 24
$299.7M
$85.8M
Q3 24
$298.7M
$93.9M
Q2 24
$286.5M
$101.2M
Total Assets
CZFS
CZFS
LUNG
LUNG
Q1 26
$120.0M
Q4 25
$3.1B
$129.3M
Q3 25
$3.1B
$138.3M
Q2 25
$3.0B
$147.2M
Q1 25
$3.0B
$150.7M
Q4 24
$3.0B
$162.8M
Q3 24
$3.0B
$167.4M
Q2 24
$2.9B
$172.6M
Debt / Equity
CZFS
CZFS
LUNG
LUNG
Q1 26
0.82×
Q4 25
0.69×
Q3 25
0.62×
Q2 25
0.54×
Q1 25
0.48×
Q4 24
0.43×
Q3 24
0.40×
Q2 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CZFS
CZFS
LUNG
LUNG
Operating Cash FlowLast quarter
$36.5M
Free Cash FlowOCF − Capex
$35.2M
FCF MarginFCF / Revenue
119.0%
Capex IntensityCapex / Revenue
4.4%
Cash ConversionOCF / Net Profit
3.49×
TTM Free Cash FlowTrailing 4 quarters
$53.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CZFS
CZFS
LUNG
LUNG
Q1 26
Q4 25
$36.5M
$-7.1M
Q3 25
$2.9M
$-8.2M
Q2 25
$6.0M
$-3.9M
Q1 25
$10.9M
$-13.2M
Q4 24
$33.2M
$-6.7M
Q3 24
$6.2M
$-7.2M
Q2 24
$3.0M
$-5.8M
Free Cash Flow
CZFS
CZFS
LUNG
LUNG
Q1 26
Q4 25
$35.2M
$-7.1M
Q3 25
$2.7M
$-8.3M
Q2 25
$5.5M
$-4.0M
Q1 25
$10.4M
$-13.5M
Q4 24
$31.9M
$-6.8M
Q3 24
$5.6M
$-7.7M
Q2 24
$2.9M
$-6.2M
FCF Margin
CZFS
CZFS
LUNG
LUNG
Q1 26
Q4 25
119.0%
-31.4%
Q3 25
9.4%
-38.4%
Q2 25
20.1%
-16.6%
Q1 25
39.2%
-60.0%
Q4 24
121.6%
-28.8%
Q3 24
22.3%
-37.6%
Q2 24
11.8%
-30.0%
Capex Intensity
CZFS
CZFS
LUNG
LUNG
Q1 26
Q4 25
4.4%
0.1%
Q3 25
0.5%
0.4%
Q2 25
1.8%
0.2%
Q1 25
2.2%
1.3%
Q4 24
5.0%
0.5%
Q3 24
2.5%
2.0%
Q2 24
0.5%
2.3%
Cash Conversion
CZFS
CZFS
LUNG
LUNG
Q1 26
Q4 25
3.49×
Q3 25
0.29×
Q2 25
0.71×
Q1 25
1.44×
Q4 24
4.16×
Q3 24
0.83×
Q2 24
0.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons